CRB Monitor Securities Update | May 2026
When the U.S. Department of Justice (D.O.J.) and Drug Enforcement Administration (D.E.A.) moved FDA-approved cannabis products and state-licensed medical marijuana ...
When the U.S. Department of Justice (D.O.J.) and Drug Enforcement Administration (D.E.A.) moved FDA-approved cannabis products and state-licensed medical marijuana ...
Cannabis-themed equities experienced a highly volatile, but news-driven month in April 2026, largely shaped by shifting U.S. federal policy expectations. ...
Once again, cannabis-related equities began 2026 with weakness, extending CRBs’ multi-year underperformance relative to global, broad market indexes. Cannabis-themed benchmarks ...
As has been the case for several years, stakeholders in the cannabis space were treated to a combination of legislative ...
For the better part of the last five years, we have used this space to offer monthly commentary on the ...
This month we are taking fresh look at the near-term health of the largest 20 pure play Tier 1 CRBs, ...
